Statins and new-onset diabetes in primary prevention setting: an updated meta-analysis stratified by baseline diabetes risk
Aims The use of statins has been associated with an increased risk of new-onset diabetes. The characteristics of the population could influence this association. The objective of this study was to determine the risk of new-onset diabetes with the use of statins in patients in primary prevention, wit...
Gespeichert in:
| Veröffentlicht in: | Acta diabetologica 2024-03, Vol.61 (3), p.351-360 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 360 |
|---|---|
| container_issue | 3 |
| container_start_page | 351 |
| container_title | Acta diabetologica |
| container_volume | 61 |
| creator | Masson, Walter Lobo, Martín Barbagelata, Leandro Nogueira, Juan P. |
| description | Aims
The use of statins has been associated with an increased risk of new-onset diabetes. The characteristics of the population could influence this association. The objective of this study was to determine the risk of new-onset diabetes with the use of statins in patients in primary prevention, with an assessment of the results according to the baseline risk of developing diabetes of the included population.
Methods
We performed an updated meta-analysis including randomized trials of statin therapy in primary prevention settings that report new-onset diabetes. The rate of new cases of diabetes in the control arms was estimated for each study. The studies were classified into two groups (low rate: |
| doi_str_mv | 10.1007/s00592-023-02205-w |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2886941772</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2967152748</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-7ebd63874f9ee6ff6839ab2e5c1dffac430b765476cee3dce99d972fc18209733</originalsourceid><addsrcrecordid>eNp9kU9P3DAQxa0KVCjtF-gBWeLCJeA_SRz3hhC0SEgcoGfLicfIkHW2HofVql8e092WigOH0Yw0v_dG9iPkK2cnnDF1iow1WlRMyFKCNdXqA9nntRRVI6Tc-W_eI58QHxjjQsnuI9mTSstaSL5Pft9mm0NEaqOjEVbVFBEydcH2kAFpiHSZwsKmdenwBDGHKdKCFNH9t6Ki89LZDI4uINvKRjuuMSDFnIqvD2XRr2lvEcYQ4dU3BXz8THa9HRG-bPsB-Xl5cXf-o7q--X51fnZdDVK0uVLQu1Z2qvYaoPW-7aS2vYBm4M57O9SS9aptatUOANINoLXTSviBd4JpJeUBOd74LtP0awbMZhFwgHG0EaYZjei6VtdcKVHQozfowzSn8qhC6VbxRqi6K5TYUEOaEBN4s_0jw5l5icZsojElGvMnGrMqosOt9dwvwP2T_M2iAHIDYFnFe0ivt9-xfQY2d5wr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2967152748</pqid></control><display><type>article</type><title>Statins and new-onset diabetes in primary prevention setting: an updated meta-analysis stratified by baseline diabetes risk</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Masson, Walter ; Lobo, Martín ; Barbagelata, Leandro ; Nogueira, Juan P.</creator><creatorcontrib>Masson, Walter ; Lobo, Martín ; Barbagelata, Leandro ; Nogueira, Juan P.</creatorcontrib><description>Aims
The use of statins has been associated with an increased risk of new-onset diabetes. The characteristics of the population could influence this association. The objective of this study was to determine the risk of new-onset diabetes with the use of statins in patients in primary prevention, with an assessment of the results according to the baseline risk of developing diabetes of the included population.
Methods
We performed an updated meta-analysis including randomized trials of statin therapy in primary prevention settings that report new-onset diabetes. The rate of new cases of diabetes in the control arms was estimated for each study. The studies were classified into two groups (low rate: < 7.5 events per 1000 patients-year; high rate; ≥ 7.5 events per 1000 patients-year). The fixed-effects model was performed.
Results
Eight studies (70,453 patients) were included. Globally, statin therapy was associated with an increased risk of new-onset diabetes (OR 1.1; 95% CI 1.0–1.2,
I
2
35%)
.
When we analyzed the studies according to the baseline diabetes risk in the control groups, the results showed that there was a greater risk only in the studies with a high baseline rate (OR 1.2; 95% CI 1.1–1.3,
I
2
0%; interaction
p
value = 0.01).
Conclusion
Globally, the use of statins in patients in primary prevention was associated with an increased risk of new-onset diabetes. In the stratified analysis, this association was observed only in the group of studies with a high baseline rate of events.</description><identifier>ISSN: 1432-5233</identifier><identifier>ISSN: 0940-5429</identifier><identifier>EISSN: 1432-5233</identifier><identifier>DOI: 10.1007/s00592-023-02205-w</identifier><identifier>PMID: 37934231</identifier><language>eng</language><publisher>Milan: Springer Milan</publisher><subject>Cardiovascular Diseases - prevention & control ; Clinical trials ; Diabetes ; Diabetes mellitus ; Diabetes Mellitus - chemically induced ; Diabetes Mellitus - epidemiology ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Internal Medicine ; Medicine ; Medicine & Public Health ; Meta-analysis ; Metabolic Diseases ; Original Article ; Prevention ; Primary Prevention ; Statins</subject><ispartof>Acta diabetologica, 2024-03, Vol.61 (3), p.351-360</ispartof><rights>Springer-Verlag Italia S.r.l., part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. Springer-Verlag Italia S.r.l., part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c326t-7ebd63874f9ee6ff6839ab2e5c1dffac430b765476cee3dce99d972fc18209733</cites><orcidid>0000-0002-5620-6468</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00592-023-02205-w$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00592-023-02205-w$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37934231$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Masson, Walter</creatorcontrib><creatorcontrib>Lobo, Martín</creatorcontrib><creatorcontrib>Barbagelata, Leandro</creatorcontrib><creatorcontrib>Nogueira, Juan P.</creatorcontrib><title>Statins and new-onset diabetes in primary prevention setting: an updated meta-analysis stratified by baseline diabetes risk</title><title>Acta diabetologica</title><addtitle>Acta Diabetol</addtitle><addtitle>Acta Diabetol</addtitle><description>Aims
The use of statins has been associated with an increased risk of new-onset diabetes. The characteristics of the population could influence this association. The objective of this study was to determine the risk of new-onset diabetes with the use of statins in patients in primary prevention, with an assessment of the results according to the baseline risk of developing diabetes of the included population.
Methods
We performed an updated meta-analysis including randomized trials of statin therapy in primary prevention settings that report new-onset diabetes. The rate of new cases of diabetes in the control arms was estimated for each study. The studies were classified into two groups (low rate: < 7.5 events per 1000 patients-year; high rate; ≥ 7.5 events per 1000 patients-year). The fixed-effects model was performed.
Results
Eight studies (70,453 patients) were included. Globally, statin therapy was associated with an increased risk of new-onset diabetes (OR 1.1; 95% CI 1.0–1.2,
I
2
35%)
.
When we analyzed the studies according to the baseline diabetes risk in the control groups, the results showed that there was a greater risk only in the studies with a high baseline rate (OR 1.2; 95% CI 1.1–1.3,
I
2
0%; interaction
p
value = 0.01).
Conclusion
Globally, the use of statins in patients in primary prevention was associated with an increased risk of new-onset diabetes. In the stratified analysis, this association was observed only in the group of studies with a high baseline rate of events.</description><subject>Cardiovascular Diseases - prevention & control</subject><subject>Clinical trials</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus - chemically induced</subject><subject>Diabetes Mellitus - epidemiology</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Meta-analysis</subject><subject>Metabolic Diseases</subject><subject>Original Article</subject><subject>Prevention</subject><subject>Primary Prevention</subject><subject>Statins</subject><issn>1432-5233</issn><issn>0940-5429</issn><issn>1432-5233</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9P3DAQxa0KVCjtF-gBWeLCJeA_SRz3hhC0SEgcoGfLicfIkHW2HofVql8e092WigOH0Yw0v_dG9iPkK2cnnDF1iow1WlRMyFKCNdXqA9nntRRVI6Tc-W_eI58QHxjjQsnuI9mTSstaSL5Pft9mm0NEaqOjEVbVFBEydcH2kAFpiHSZwsKmdenwBDGHKdKCFNH9t6Ki89LZDI4uINvKRjuuMSDFnIqvD2XRr2lvEcYQ4dU3BXz8THa9HRG-bPsB-Xl5cXf-o7q--X51fnZdDVK0uVLQu1Z2qvYaoPW-7aS2vYBm4M57O9SS9aptatUOANINoLXTSviBd4JpJeUBOd74LtP0awbMZhFwgHG0EaYZjei6VtdcKVHQozfowzSn8qhC6VbxRqi6K5TYUEOaEBN4s_0jw5l5icZsojElGvMnGrMqosOt9dwvwP2T_M2iAHIDYFnFe0ivt9-xfQY2d5wr</recordid><startdate>20240301</startdate><enddate>20240301</enddate><creator>Masson, Walter</creator><creator>Lobo, Martín</creator><creator>Barbagelata, Leandro</creator><creator>Nogueira, Juan P.</creator><general>Springer Milan</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5620-6468</orcidid></search><sort><creationdate>20240301</creationdate><title>Statins and new-onset diabetes in primary prevention setting: an updated meta-analysis stratified by baseline diabetes risk</title><author>Masson, Walter ; Lobo, Martín ; Barbagelata, Leandro ; Nogueira, Juan P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-7ebd63874f9ee6ff6839ab2e5c1dffac430b765476cee3dce99d972fc18209733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Cardiovascular Diseases - prevention & control</topic><topic>Clinical trials</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus - chemically induced</topic><topic>Diabetes Mellitus - epidemiology</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Meta-analysis</topic><topic>Metabolic Diseases</topic><topic>Original Article</topic><topic>Prevention</topic><topic>Primary Prevention</topic><topic>Statins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Masson, Walter</creatorcontrib><creatorcontrib>Lobo, Martín</creatorcontrib><creatorcontrib>Barbagelata, Leandro</creatorcontrib><creatorcontrib>Nogueira, Juan P.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Acta diabetologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Masson, Walter</au><au>Lobo, Martín</au><au>Barbagelata, Leandro</au><au>Nogueira, Juan P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Statins and new-onset diabetes in primary prevention setting: an updated meta-analysis stratified by baseline diabetes risk</atitle><jtitle>Acta diabetologica</jtitle><stitle>Acta Diabetol</stitle><addtitle>Acta Diabetol</addtitle><date>2024-03-01</date><risdate>2024</risdate><volume>61</volume><issue>3</issue><spage>351</spage><epage>360</epage><pages>351-360</pages><issn>1432-5233</issn><issn>0940-5429</issn><eissn>1432-5233</eissn><abstract>Aims
The use of statins has been associated with an increased risk of new-onset diabetes. The characteristics of the population could influence this association. The objective of this study was to determine the risk of new-onset diabetes with the use of statins in patients in primary prevention, with an assessment of the results according to the baseline risk of developing diabetes of the included population.
Methods
We performed an updated meta-analysis including randomized trials of statin therapy in primary prevention settings that report new-onset diabetes. The rate of new cases of diabetes in the control arms was estimated for each study. The studies were classified into two groups (low rate: < 7.5 events per 1000 patients-year; high rate; ≥ 7.5 events per 1000 patients-year). The fixed-effects model was performed.
Results
Eight studies (70,453 patients) were included. Globally, statin therapy was associated with an increased risk of new-onset diabetes (OR 1.1; 95% CI 1.0–1.2,
I
2
35%)
.
When we analyzed the studies according to the baseline diabetes risk in the control groups, the results showed that there was a greater risk only in the studies with a high baseline rate (OR 1.2; 95% CI 1.1–1.3,
I
2
0%; interaction
p
value = 0.01).
Conclusion
Globally, the use of statins in patients in primary prevention was associated with an increased risk of new-onset diabetes. In the stratified analysis, this association was observed only in the group of studies with a high baseline rate of events.</abstract><cop>Milan</cop><pub>Springer Milan</pub><pmid>37934231</pmid><doi>10.1007/s00592-023-02205-w</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-5620-6468</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1432-5233 |
| ispartof | Acta diabetologica, 2024-03, Vol.61 (3), p.351-360 |
| issn | 1432-5233 0940-5429 1432-5233 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2886941772 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Cardiovascular Diseases - prevention & control Clinical trials Diabetes Diabetes mellitus Diabetes Mellitus - chemically induced Diabetes Mellitus - epidemiology Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Internal Medicine Medicine Medicine & Public Health Meta-analysis Metabolic Diseases Original Article Prevention Primary Prevention Statins |
| title | Statins and new-onset diabetes in primary prevention setting: an updated meta-analysis stratified by baseline diabetes risk |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T14%3A14%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Statins%20and%20new-onset%20diabetes%20in%20primary%20prevention%20setting:%20an%20updated%20meta-analysis%20stratified%20by%20baseline%20diabetes%20risk&rft.jtitle=Acta%20diabetologica&rft.au=Masson,%20Walter&rft.date=2024-03-01&rft.volume=61&rft.issue=3&rft.spage=351&rft.epage=360&rft.pages=351-360&rft.issn=1432-5233&rft.eissn=1432-5233&rft_id=info:doi/10.1007/s00592-023-02205-w&rft_dat=%3Cproquest_cross%3E2967152748%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2967152748&rft_id=info:pmid/37934231&rfr_iscdi=true |